Ümit Yavuz MALKAN, Salih AKSU, Yahya BÜYÜKAŞIK, Hakan GÖKER, Haluk DEMİROĞLU, Osman İlhami ÖZCEBE, İbrahim Celalettin HAZNEDAROĞLU, Mustafa VELET, Nilgün SAYINALP, Olgu Erkin ÇINAR, Ayşe KARATAŞ, Batuhan ERDOĞDU, Mine KARADENİZ

Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem cell transplantation

Background/aim: Thrombocytopenia is a common complication following hematopoietic stem cell transplantation (HSCT). Eltrombopag has been used in thrombocytopenia treatment after HSCT in recent years. Herein, we present our experience of 25 patients treated with eltrombopag for post-HSCT thrombocytopenia. Materials and methods: Fifteen autologous hematopoietic stem cell transplantation (AHSCT) and 10 allogenic hematopoietic stem cell transplantation (allo-HSCT) recipients treated with eltrombopag for treatment of prolonged isolated thrombocytopenia (PIT) or secondary failure of platelet recovery (SFPR) in the stem cell transplantation unit of Hacettepe University Hematology Department between 2017 and 2021 were included in the study. The primary endpoint of this study is eltrombopag response in patients diagnosed with PIT or SFPR. Platelet count above 50,000/mm3 for five consecutive days without platelet transfusion was considered as eltrombopag response. Overall survival (OS) analyses were calculated based on the time between HSCT and death from any cause. The patients who were alive at the last follow-up were censored at this time for calculation of OS analyses. Results: AHSCT (66.7% (10/15)) and allo-HSCT (50% (5/10)) recipients responded to eltrombopag for the treatment of post-HSCT thrombocytopenia. There was no excess toxicity related to the eltrombopag use. The median response duration of allo-HSCT recipients and AHSCT recipients were 41 (13–104) days and 50 (7–342) days, respectively. There was a statistically significant OS duration difference between the responders and nonresponders in allo-HSCT and AHSCT recipients with p values of 0.005 and 0.02, respectively. Conclusion: Eltrombopag is promising for the treatment of thrombocytopenia after AHSCT and allo-HSCT in terms of efficacy and safety.

PDF

___

1. Yaman Y, Elli M, Şahin Ş, Özdilli K, Bilgen H et al. Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single-centre experience. Pediatric Transplantation 2021; 25(5): e13962.doi: 10.1111/petr.13962
2. First LR, Smith BR, Lipton J, Nathan DG, Parkman R et al. Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes. Blood 1985; 65(2): 368-374.
3. Bolwell B, Pohlman B, Sobecks R, Andresen S, Brown S et al. Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant. Bone Marrow Transplantation 2004; 33(4): 419-23.doi: 10.1038/sj.bmt.1704330
4. Kong Y, Hu Y, Zhang XH, Wang YZ, Mo XD et al. Association between an impaired bone marrow vascular microenvironment and prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 2014; 20(8): 1190-1197.doi: 10.1016/j. bbmt.2014.04.015
5. Mahat U, Rotz SJ, and Hanna R. Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation. Biology of Blood Marrow Transplantation 2020; 26(3): e65-e73.doi: 10.1016/j. bbmt.2019.12.003
6. Nash RA, Kurzrock R, DiPersio J, Vose J, Linker C et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biology of Blood Marrow Transplantation 2000; 6(1): 25-34.doi: 10.1016/s1083-8791(00)70049-8
7. Uria-Oficialdegui ML, Alonso L, Benitez-Carabante MI, Renedo B, Oliveras M et al. Use of eltrombopag for the treatment of poor graft function after hematopoietic stem cell transplantation in children. Pediatric Transplantation 2021; 25(4): e14010.doi: 10.1111/petr.14010
8. Nampoothiri RV, Ho L, McEwan C, Pasic I, Lam W et al. Efficacy and cost analysis of eltrombopag in thrombocytopenia and poor graft function post allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation 2021; 56(10): 2471-2476.doi: 10.1038/s41409-021-01362-2
9. Giammarco S, Sica S, Chiusolo P, Laurenti L, Sorá F et al. Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study. International Journal of Hematology 2021; 114(2): 228-234.doi: 10.1007/s12185-021-03153-3
10. Ahmed S, Bashir Q, Bassett R, Poon MC, Valdez B et al. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, PlaceboControlled Trial. Transplantion and Cellular Therapy 2021; 27(5): 430.e1-430.e7.doi: 10.1016/j.jtct.2021.02.004
11. Labrador J, López-Corral L, Vazquez L, Sánchez-Guijo F, Guerrero C et al. Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant. British Journal of Haematology 2015; 169(5): 719-25.doi: 10.1111/bjh.13344
12. Vasudevan Nampoothiri R and Kumar R. Eltrombopag: Role in Cytopenias Following Hematopoietic Stem Cell Transplantation. Indian Journal of Hematology and Blood Transfusion 2020; 36(2): 238-245.doi: 10.1007/s12288-019- 01194-7
13. Bento L, Bastida JM, García-Cadenas I, García-Torres E, Rivera D et al. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant. Biology of Blood Marrow Transplantation 2019; 25(9): 1825-1831.doi: 10.1016/j.bbmt.2019.05.023
14. Fu H, Zhang X, Han T, Mo X, Wang Y et al. Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplantation 2019; 54(8): 1310-1318.doi: 10.1038/s41409-019-0435-2
15. Yuan C, Boyd AM, Nelson J, Patel RD, Varela JC et al. Eltrombopag for Treating Thrombocytopenia after Allogeneic Stem Cell Transplantation. Biology of Blood Marrow Transplantation 2019; 25(7): 1320-1324.doi: 10.1016/j. bbmt.2019.01.027
16. Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K et al. Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood Marrow Transplantation 2016; 22(5): 919-24.doi: 10.1016/j.bbmt.2016.01.018
17. Gupta AK, Srinivasan P, Das G, Meena JP, Tanwar P et al. Eltrombopag post autologous hematopoietic stem cell transplant - an emerging indication in younger pediatric patients. American Journal of Blood Research 2021; 11(2): 168-171
18. Reid R, Bennett JM, Becker M, Chen Y, Milner L et al. Use of eltrombopag, a thrombopoietin receptor agonist, in posttransplantation thrombocytopenia. American Journal of Hematology 2012; 87(7): 743-5.doi: 10.1002/ajh.23225
19. Raut SS, Shah SA, Sharanangat VV, Shah KM, Patel KA et al. Safety and Efficacy of Eltrombopag in Post-hematopoietic Stem Cell Transplantation (HSCT) Thrombocytopenia. Indian Journal of Hematology and Blood Transfusion 2015; 31(4): 413-5.doi: 10.1007/s12288-014-0491-0
20. Zaja F, Geromin A, Patriarca F, Puglisi S, Cerno M et al. Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant. American Journal Hematology 2011; 86(9): 790-2.doi: 10.1002/ajh.22086
21. Blumberg N, Heal JM, and Phillips GL. Platelet transfusions: trigger, dose, benefits, and risks. F1000 Medicine Reports 2010; 2: 5.doi: 10.3410/m2-5
22. Samarkandi H, Al Nahedh M, Alfattani A, Alsharif F, Bakshi N et al. Evaluation of eltrombopag in thrombocytopenia post Hematopoietic cell transplantation: Retrospective observational trial. Hematology/Oncology Stem Cell Therapy 2020.doi: 10.1016/j.hemonc.2020.07.006